Company: NDRA
Filing Date: 2025-11-14
Form Type: 8-K
Source: 0001213900-25-110897
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

As previously disclosed in a Current Report on
Form 8-K filed with the SEC on May 30, 2025 (the “ Original 8-K”), on May 27, 2025, ENDRA Life Sciences Inc. (the “ Company”)
received a notification letter from the Nasdaq Listing Qualifications Staff (the “ Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq”)
notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the “ Rule”).

As noted in the Original 8-K, the Company had
until July 11, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain
compliance on July 11, 2025 and subsequently provided the Staff with additional materials. On October 31, 2025, the Company received written
notice that, based on review of the compliance plan and additional materials, the Staff had granted the Company an extension to November
24, 2025 to regain compliance with the Rule. The Company is filing this Current Report on Form 8-K (this “ Report”) to provide
an update to its compliance with the Rule.

On October 15, 2025, the Company closed a private
placement offering (the “ Offering”) of an aggregate of 744,340 shares of common stock of the Company, par value $0.0001 per
share (the “ Common Stock”), or prefunded warrants in lieu thereof, and warrants to purchase an aggregate of up to 1,488,680
shares of Common Stock at a per share exercise price of $6.32 (or $6.81 in respect of warrants purchased by a member of the Company’s
board of directors), for gross proceeds of approximately $4.9 million. On October 23, 2025, the Company announced that it had launched
its digital asset treasury strategy by the purchase of 78,863.1 HYPE tokens.

Additionally, on October 29, 2025, the Company
entered into an At-The-Market Issuance Sales Agreement with Lucid Capital Markets, LLC, as sales agent (“ Lucid”), pursuant
to which the Company may offer and sell, from time to time through Lucid, shares of Common Stock for aggregate